GlaxoSmithKline has announced that its new antiseptic gel to prevent umbilical cord infections in newborn infants has been recommended by a European agency.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive scientific opinion for the chlorhexidine gel, which is designed to combat omphalitis in developing countries.
“GlaxoSmithKline has received a CHMP recommendation for a new antiseptic gel for newborn umbilical cord infections in developing countries.“
Developed as part of a partnership between GlaxoSmithKline and Save the Children, the gel was created by reformulating the antiseptic solution used in the company's Corsodyl mouthwash.
It has been specially designed to be stable in hot and humid conditions, avoiding the need for refrigeration and helping to simplify distribution to remote communities.
Patrick Vallance, president for pharmaceutical research and development at GlaxoSmithKline, said: "This is a real illustration of how collaboration can stimulate imaginative responses to tough challenges."
Next, the firm will submit local regulatory applications for the gel in low-income countries with moderate to high rates of neonatal deaths. If approved, GlaxoSmithKline will sell the gel under the trade name Umbipro at a not-for-profit price.See all the latest jobs in Pharmaceutical